StockMarketWire.com - Hikma Pharmaceuticals said it expected revenues in its generics business to be closer to the top end of its guidance range following strong demand and operational improvements.

For the full year, the pharma company said it now expected generics revenue to be closer to the top end of its guidance range of $690m to $720M and continued to expect core operating margin to be in the range of 16% to 18%.

For its injectables business revenue guidance was maintained in the range of $870m to $900m for the full year in 2019 and core operating margin in the range of 36% to 38%.

Its injectables business in the US had experienced good demand, which more than offset increased competition and the gradual decline in revenue from shortages of pain management products, as expected.

Its branded business, meanwhile, benefitted from 'strong growth' in most markets more than offsetting lower sales in Algeria.

'We continue to expect branded revenue growth in constant currency to be in the mid-single digits for the full year in 2019,' the company said.




Story provided by StockMarketWire.com